CD19 Universal CAR-γδ T Cells Therapy(Guangzhou Bio-Gene Technology)

N/A

Report date: 2024/12/20 15:44:50

Base Information

Drug NameCD19 Universal CAR-γδ T Cells Therapy(Guangzhou Bio-Gene Technology)
Drug Alias NameCD19 Universal CAR-γδT Cells Therapy(Guangzhou Bio-Gene Technology Co Ltd)
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy +[5] 
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Bio-Gene Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Bio-Gene Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A